Targeted Sodium Acetate Liposomes for Hepatocytes and Kupffer Cells: An Oral Dual-Targeted Therapeutic Approach for Non-Alcoholic Fatty Liver Disease Alleviation DOI Open Access
Yichao Hou,

Xilong Gao,

Jia‐Hui Gong

и другие.

Nutrients, Год журнала: 2025, Номер 17(5), С. 930 - 930

Опубликована: Март 6, 2025

Background/Objectives: Sodium acetate (NaA) has demonstrated potential in improving non-alcoholic fatty liver disease (NAFLD) by targeting hepatocytes and Kupffer cells. However, its clinical application is hindered low oral bioavailability insufficient concentrations. Liposomes, with their capacity to encapsulate water-soluble drugs be surface-modified, offer a promising solution for targeted drug delivery. Methods: We designed NaA-loaded liposomes modified sodium cholate (SC) mannose (MAN) (NaA@SC/MAN-LPs) target Results: The NaA@SC/MAN-LPs had mean diameter of approximately 100 nm positive surface charge. Compared free NaA, significantly extended the serum half-life from 2.85 h 15.58 h, substantially vivo bioavailability. In distribution studies revealed that peak time 15 min 60 increased hepatic accumulation 3.75 times NaA. vitro cell experiments, reduced lipid droplet, triglycerides (TG), total cholesterol (TC) acid-induced hepatocyte steatosis model suppressed proinflammation lipopolysaccharide (LPS)-activated inflammation model. Free NaA effectively improved deposition NAFLD mice. Furthermore, decreased TG, TC, relative area droplets 30.44%, 15.26%, 55.83%, compared macrophage infiltration pro-inflammatory response. Conclusions: effective dual effects on cells, pathogenesis NAFLD, This study provides new strategy developing safe NAFLD.

Язык: Английский

Targeted Sodium Acetate Liposomes for Hepatocytes and Kupffer Cells: An Oral Dual-Targeted Therapeutic Approach for Non-Alcoholic Fatty Liver Disease Alleviation DOI Open Access
Yichao Hou,

Xilong Gao,

Jia‐Hui Gong

и другие.

Nutrients, Год журнала: 2025, Номер 17(5), С. 930 - 930

Опубликована: Март 6, 2025

Background/Objectives: Sodium acetate (NaA) has demonstrated potential in improving non-alcoholic fatty liver disease (NAFLD) by targeting hepatocytes and Kupffer cells. However, its clinical application is hindered low oral bioavailability insufficient concentrations. Liposomes, with their capacity to encapsulate water-soluble drugs be surface-modified, offer a promising solution for targeted drug delivery. Methods: We designed NaA-loaded liposomes modified sodium cholate (SC) mannose (MAN) (NaA@SC/MAN-LPs) target Results: The NaA@SC/MAN-LPs had mean diameter of approximately 100 nm positive surface charge. Compared free NaA, significantly extended the serum half-life from 2.85 h 15.58 h, substantially vivo bioavailability. In distribution studies revealed that peak time 15 min 60 increased hepatic accumulation 3.75 times NaA. vitro cell experiments, reduced lipid droplet, triglycerides (TG), total cholesterol (TC) acid-induced hepatocyte steatosis model suppressed proinflammation lipopolysaccharide (LPS)-activated inflammation model. Free NaA effectively improved deposition NAFLD mice. Furthermore, decreased TG, TC, relative area droplets 30.44%, 15.26%, 55.83%, compared macrophage infiltration pro-inflammatory response. Conclusions: effective dual effects on cells, pathogenesis NAFLD, This study provides new strategy developing safe NAFLD.

Язык: Английский

Процитировано

0